Prague Med. Rep. 2013, 114, 57-71

https://doi.org/10.14712/23362936.2014.24

Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer – Three Years of Experience

Z. Pechačová1, Milada Zemanová1,*,  T. Haruštiak2, P. Vítek3, P. Fencl4

1Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
23rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
3Institute of Radiation Oncology, First Faculty of Medicine, Charles University in Prague and Hospital Bulovka, Prague, Czech Republic
4PET Centre, Hospital Na Homolce, Prague, Czech Republic

References

1. Boige, V., Pignon, J., Saint-Aubert, B., Lasser, P., Conroy, T., Bouché, O., Segol, P., Bedenne, L., Rougier, P., Ychou, M. (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J. Clin. Oncol. 25, 4510.
2. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., van de Velde, C. J., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., Chua, Y. J., MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20. <https://doi.org/10.1056/NEJMoa055531>
3. Dikken, J. L., van Sandick, J. W., Maurits Swellengrebel, H. A., Lind, P. A., Putter, H., Jansen, E. P., Boot, H., van Grieken, N. C., van de Velde, C. J., Verheij, M., Cats, A. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11, 329. <https://doi.org/10.1186/1471-2407-11-329> <PubMed>
4. Enestvedt, C. K., Perry, K. A., Kim, C., McConnell, P. W., Diggs, B. S., Vernon, A., O’Rourke, R. W., Luketich, J. D., Hunter, J. G., Jobe, B. A. (2010) Trends in the management of esophageal carcinoma based on provider volume: treatment practices of 618 esophageal surgeons. Dis. Esophagus 23(2), 136–144. <https://doi.org/10.1111/j.1442-2050.2009.00985.x>
5. Fiorica, F., DiBona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., Falchi, A. M., Craxì, A., Cammà, C. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53(7), 925–930. <https://doi.org/10.1136/gut.2003.025080> <PubMed>
6. Gebski, V., Burmeister, B., Smithers, B. M., Foo, K., Zalcberg, J., Simes, J., Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8(3), 226–234. <https://doi.org/10.1016/S1470-2045(07)70039-6>
7. Gravalos, C., Jimeno, A. (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523–1529. <https://doi.org/10.1093/annonc/mdn169>
8. Institute of Health Information and Statistics of the Czech Republic, National Oncology Register (2011) Cancer Incidence 2008 in the Czech Republic. Institute of Health Information and Statistics of the Czech Republic, Prague.
9. Iyer, R., Wilkinson, N., Demmy, T., Javle, M. (2004) Controversies in the multimodality management of locally advanced esophageal cancer: Evidence-based review of surgery alone and combined-modality therapy. Ann. Surg. Oncol. 11, 665–673. <https://doi.org/10.1245/ASO.2004.10.026>
10. Langer, R., Ott, K., Feith, M., Lordick, F., Siewert, J. R., Becker, K. (2009) Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod. Pathol. 22(12), 1555–1563. <https://doi.org/10.1038/modpathol.2009.123>
11. Lee, J., Lim do, H., Kim, S., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Choi, M. G., Sohn, T. S., Noh, J. H., Bae, J. M., Ahn, Y. C., Sohn, I., Jung, S. H., Park, C. K., Kim, K. M., Kang, W. K. (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J. Clin. Oncol. 30(3), 268–273. <https://doi.org/10.1200/JCO.2011.39.1953>
12. Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., Martenson, J. A. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725–730. <https://doi.org/10.1056/NEJMoa010187>
13. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727–1734.
14. Okines, A. F., Ashley, S. E., Cunningham, D., Oates, J., Turner, A., Webb, J., Saffery, C., Chua, Y. J., Chau, I. (2010) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Clin. Oncol. 28(25), 3945–3950. <https://doi.org/10.1200/JCO.2010.29.2847>
15. Reynolds, J. V., Muldoon, C., Hollywood, D., Ravi, N., Rowley, S., O’Byrne, K., Kennedy, J., Murphy, T. J. (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann. Surg. 245(5), 707–716. <https://doi.org/10.1097/01.sla.0000254367.15810.38> <PubMed>
16. Siewert, J. R., Stein, H. J. (1996) Carcinoma of the cardia: Carcinoma of the gastroesophageal junction – classification, pathology and extent of resection. Dis. Esophagus 9, 173–182. <https://doi.org/10.1093/dote/9.4.278>
17. Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H. J., Riera-Knorrenschild, J., Langer, P., Engenhart-Cabillic, R., Bitzer, M., Königsrainer, A., Budach, W., Wilke, H. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol. 27(6), 851–856. <https://doi.org/10.1200/JCO.2008.17.0506>
18. Thuss-Patience, P. C., Hofheinz, R. D., Arnold, D., Florschütz, A., Daum, S., Kretzschmar, A., Mantovani-Löffler, L., Bichev, D., Breithaupt, K., Kneba, M., Schumacher, G., Glanemann, M., Schlattmann, P., Reichardt, P., Gahn, B. (2012) Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann. Oncol. 23(11), 2827–2834. <https://doi.org/10.1093/annonc/mds129>
19. Walsh, T. N., Noonan, A., Hollywood, D., Kelly, A., Keeling, N., Hennessy, T. P. (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335(7), 462–467. <https://doi.org/10.1056/NEJM199608153350702>
20. Zemanova, M., Petruzelka, L., Pazdro, A., Kralova, D., Smejkal, M., Pazdrova, G., Honova, H. (2010) Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis. Esophagus 23(2), 160–167. <https://doi.org/10.1111/j.1442-2050.2009.00984.x>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive